You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 9,663,579


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,663,579
Title:Formulation for anti-.alpha.4.beta.7 antibody
Abstract: Methods for achieving clinical response of Crohn\'s disease in a human patient are described comprising administration of an antibody that has binding specificity for human .alpha.4.beta.7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-.alpha.4.beta.7 antibody in vivo.
Inventor(s): Fox; Irving H. (Wellesley, MA), Scholz; Catherine (Woburn, MA)
Assignee: Millennium Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:15/215,012
Patent Claims:1. A method for achieving clinical response of Crohn's disease in a human patient, comprising intravenously administering to a human patient with Crohn's disease, wherein said human patient had a lack of an adequate response with, lost response to, or was intolerant to a TNF.alpha. antagonist: a first dose of 300 mg of an antibody that has binding specificity for human .alpha.4.beta.7 integrin, a second dose of 300 mg of the antibody two weeks after the first dose, and a third dose of 300 mg of the antibody six weeks after the first dose, wherein the antibody comprises the heavy chain variable region sequence of amino acids 20 to 140 of SEQ ID NO:2, and the light chain variable region sequence of amino acids 20 to 131 of SEQ ID NO:4.

2. The method of claim 1, wherein heavy chain of the antibody comprises amino acids 20 to 470 of SEQ ID NO:2, and the light chain of the antibody comprises amino acids 20 to 238 of SEQ ID NO:4.

3. The method of claim 1, wherein each dose is intravenously administered as an infusion over about 30 minutes.

4. The method of claim 1, wherein the Crohn's disease is moderate to severely active Crohn's disease.

5. A method for achieving clinical response of Crohn's disease in a human patient, comprising intravenously administering to a human patient with Crohn's disease, wherein the human patient had a lack of an adequate response with, lost response to, or was intolerant to a TNF.alpha. antagonist: a first dose of 300 mg of vedolizumab, a second dose of 300 mg of vedolizumab two weeks after the first dose, and a third dose of 300 mg of vedolizumab six weeks after the first dose.

6. The method of claim 5, wherein the Crohn's disease is moderate to severely active Crohn's disease.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.